Amicus Therapeutics (FOLD) was Initiated by BofA/Merrill to “Buy” and the brokerage firm has set the Price Target at $10. BofA/Merrill advised their investors in a research report released on May 18, 2016.
Many Wall Street Analysts have commented on Amicus Therapeutics. Robert W. Baird Initiated Amicus Therapeutics on Apr 14, 2016 to “Neutral”, Price Target of the shares are set at $9.Company shares were Reiterated by Chardan Capital Markets on Apr 12, 2016 to “Buy”, Firm has raised the Price Target to $ 15 from a previous price target of $10 .Amicus Therapeutics was Initiated by Goldman to “Sell” on Mar 30, 2016.
Amicus Therapeutics opened for trading at $6.43 and hit $6.81 on the upside on Monday, eventually ending the session at $6.79, with a gain of 7.10% or 0.45 points. The heightened volatility saw the trading volume jump to 16,28,822 shares. Company has a market cap of $863 M.
In a different news, on Nov 10, 2015, Margaret G Mcglynn (director) purchased 10,000 shares at $10.27 per share price. According to the SEC, on Oct 5, 2015, Kenneth Peist (VP, Legal & IP) sold 10,000 shares at $13.14 per share price. On Oct 5, 2015, Daphne Quimi (Vice President Finance) sold 11,250 shares at $13.13 per share price, according to the Form-4 filing with the securities and exchange commission.
Amicus Therapeutics Inc. is a biopharmaceutical company. The Company focuses on the discovery development and commercialization of medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold) a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs including Fabry disease Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease SD-101 for Epidermolysis Bullosa (EB) as well as ERT products for Fabry disease Pompe disease and MPS I.